Comparative Pharmacology
Head-to-head clinical analysis: PRILOCAINE HYDROCHLORIDE versus XYLOCAINE 1 5 W DEXTROSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRILOCAINE HYDROCHLORIDE versus XYLOCAINE 1 5 W DEXTROSE 7 5.
PRILOCAINE HYDROCHLORIDE vs XYLOCAINE 1.5% W/ DEXTROSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prilocaine hydrochloride is an amino amide local anesthetic that reversibly blocks sodium channels in nerve cell membranes, inhibiting nerve impulse propagation.
Lidocaine is an amide-type local anesthetic that blocks sodium channels, thereby inhibiting the propagation of action potentials in peripheral nerves, leading to local anesthesia.
Adults: 4 mg/kg (max 200 mg) via infiltration or nerve block; may repeat after 2 hours with 50% of initial dose.
Spinal anesthesia: 1.5-2 mL (22.5-30 mg lidocaine) for lower extremity or perineal procedures; 2-3 mL (30-45 mg) for lower abdominal or urological procedures. Administered via lumbar puncture.
None Documented
None Documented
Terminal half-life: 1.5-2 hours (adults, normal hepatic function). Prolonged in neonates (up to 8-12 hours) due to immature hepatic metabolism and reduced clearance; may cause methemoglobinemia. Hepatic impairment increases half-life.
Terminal elimination half-life: 1.5–2 hours in adults with normal hepatic function; may be prolonged to 3–5 hours in patients with hepatic impairment or congestive heart failure.
Renal: ~95% as metabolites (primarily o-toluidine and 4-hydroxy-2-methylaniline) and <5% unchanged. Biliary/fecal: minimal (<2%).
Renal excretion of metabolites (predominantly 4-hydroxy-2,6-xylidine and conjugates) accounts for >80% of elimination; less than 10% eliminated unchanged in urine. Biliary/fecal excretion of metabolites contributes <10%.
Category C
Category C
Local Anesthetic
Local Anesthetic